Vericel VCEL 深 沪
等待开盘 07-26 09:30:00 美东时间
40.12
+0.400
+1.01%
华盛通- 最 高40.54
- 今 开40.03
- 成交量 34.51万股
- 最 低 39.665
- 昨 收 39.72
- 总市值 20.20亿
- 52周最高 63.00
- 市盈率 静 200.10
- 换手率 0.69%
- 52周最低 34.8698
- 委 比 67.45%
- 总股本 5034.30万
- 历史最高 68.94
- 量 比 0.59
- 振 幅 2.20%
- 历史最低 1.11
- 每 手 1
- 风险率 6.87%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Vericel to Report Second-Quarter 2025 Financial Results on July 31, 2025
<p>Vericel Corporation, a leader in advanced therapies for sports medicine and severe burn care, announced it will report its second-quarter 2025 financial results on July 31, 2025. Management will host a conference call and webcast at 8:30 a.m. ET to discuss financial results and business highlights. The live webcast can be accessed on Vericel's Investor Relations website, with presentation slides and a replay available. Investors can join by ph...
07-17 12:30
Vericel to Present at the Truist Securities MedTech Conference on Tuesday, June 17, 2025
Vericel Corporation will participate in a fireside chat at the Truist Securities MedTech Conference on June 17, 2025. A webcast will be available on its Investor Relations website. The company specializes in advanced therapies for sports medicine and severe burn care, with products including MACI for knee cartilage repair, Epicel for burn treatment, and NexoBrid for eschar removal. More information is available at www.vcel.com.
06-10 12:30
美股大行评级 | 高盛上调微软目标价从480美元至550美元，Snowflake获多家机构上调目标价！
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1132593314765758464.png</p><span style="color:#999999;">编者按：每日追踪华尔街最新评级与目标价，挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• 摩根大通：维持IDEAYA Biosciences(IDYA)"超配"评级，目标价从63美元升至66美元</p> <p>• Needham：上调Inogen(INGN)评级至"买入"，目标价12美元</p> <p>• E
05-23 11:19
What Analysts Are Saying About Vericel Stock
In the last three months, 4 analysts have published ratings on Vericel (NASDAQ:...
05-23 06:00
Stephens & Co. Reiterates Overweight on Vericel, Maintains $67 Price Target
Stephens & Co. analyst Mason Carrico reiterates Vericel (NASDAQ:VCEL) with a Overweight and maintains $67 price target.
05-22 21:27
Vericel Corporation Reports Record Q1 Revenue
Vericel Corporation ( ($VCEL) ) has released its Q1 earnings. Here is a breakdo...
05-09 13:26
Vericel shares are trading lower after the company reported worse-than-expected Q1 financial results.
Vericel shares are trading lower after the company reported worse-than-expected...
05-08 21:16
Vericel Sees Q2 Sales $64.248M-$65.828M vs $65.07M Est
Vericel (NASDAQ:VCEL) sees Q2 sales of $64.248 million-$65.828 million vs $65.07 million analyst estimate.
05-08 20:06
Vericel Affirms FY2025 Sales Guidance of $284.67M-$291.79M vs $286.61M Est
Vericel (NASDAQ:VCEL) affirms FY2025 sales outlook from $284.67 million-$291.79 million to $284.67 million-$291.79 million vs $286.61 million estimate.
05-08 20:06
Vericel misses top-line and bottom-line estimates; initiates Q2 and reaffirms FY25 outlook
Vericel press release (NASDAQ:VCEL): Q1 GAAP EPS of -$0.23 misses by $0.10. Revenue of $52.6M (+2.5% Y/Y) misses by $1.26M. Non-GAAP adjusted EBITDA for the quarter ended March 31, 2025 was $3.2 milli...
05-08 19:58
